Miramar Labs: Bringing A Traditional Device Model To Aesthetics
Miramar is employing a conventional product development strategy to create the first device therapy in an unconventional clinical space – hyperhidrosis, or excessive sweating. The key: a more rigorous clinical approach than usual in aesthetics. But is the market there?
You may also be interested in...
A decade ago, incuabators were seen as the best medicine for what then ailed the medical device industry, most notably a complex regulatory pathway and a difficult venture financing climate. Perhaps not surprisingly, as both the regulatory path and venture financing grew easier in the mid 2000s, incubators began to struggle, victims of their own financing problems. More recently, two huge acquisitions, Abbott's purchase of Evalve and Medtronic's of Ardian, suggest that at least one incubator, The Foundry, is proving that incubation works.
Using the first catheter therapy for the interventional treatment of hypertension, this start-up's technology may be able to reduce blood pressure where drugs have not worked, and holds future promise for heart failure and kidney disease.
Full-scale commercialization of percutaneous heart valve technology is still years away, but Evalve's new approach to mitral repair is closest to the clinic.